Transl Androl Urol 2017;6(6):1175-1183 tau.amegroups.com © Translational Andrology and Urology. All rights reserved. urological symptom and risk profile due to the difference in underlying condition (including stage and severity of disease) and location of neurological lesion.
This considerable heterogeneity compounds the availability of a single optimal medical therapy, meaning that treatments are often wide-ranging and individualized to the particular patient (3) . Myriad treatment modalities can be employed including behavioral therapies, oral pharmacotherapy, catheterization and surgery. Four key aims outlined by the European Association of Urology (EAU) that are of paramount importance when selecting treatments are protection of the upper urinary tract, improvement of urinary continence, restoration of the lower urinary tract function and improvement of patient quality of life (QoL) (4) .
Despite the availability of clinical guidelines, a survey conducted in the Netherlands found that "18% of urologists used the EAU guidelines on NGB frequently, 35% did so occasionally and 47% did not use them at all" (5) . This systematic review (SR) aims to collate evidence on the management strategies that are employed in the real world and determine whether practices are in concordance with prominent NGB clinical guidelines. This research can act as an important preliminary step in influencing future guideline recommendations to reflect what is working for physicians in the real world. This research also demonstrates how prescribing patterns in NGB may have changed over time. This article aims to describe the treatment patterns and management strategies of NGB in the real word.
Methods

Eligibility criteria
(I) Patients with any neurological condition, e.g., spina bifida, stroke, SCI, MS, PD; (II) Studies that measure treatment use e.g., percentage use, duration of use, treatment switching, combination use; (III) Real world studies, including both retrospective or prospective: cohort, case-control, cross-sectional and chart review. During the pilot search, no studies were retrieved that focused solely on adults therefore the search was expanded to include subjects of any age.
Search strategy
This SR was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines ( Figure 1) (6) .
A search was run on 15th February 2017 using a combination of free-text words and medical subject headings in MEDLINE ® , and EMBASE ® (Table S1 ). Limits were applied for studies published between the years of 1996-2017. Eligibility assessment was conducted in two stages. In the first stage, an independent reviewer (Ashley Jaggi) screened titles and abstracts for alignment with pre-defined inclusion and exclusion criteria ( Table 1) . Ten percent of included papers were cross-examined by a second independent (Francis Fatoye) reviewer. In the second stage, full versions of the included texts, acquiescent with inclusion criteria, were screened by both reviewers. Any disagreements were mediated by discussion.
Data collection and extraction
Information on the study design, patient characteristics, and treatments in NGB was extracted using a piloted data extraction form.
Summary measures
Treatment patterns were descriptively summarized using narrative review. Percentage of treatment use was summarized using ranges.
Results
A total of 116 publications were yielded. After screening titles and abstracts and removing additional duplicates (ProQuest Dialog ® removes most duplicates), 10 articles were retrieved, and the full texts were reviewed. Based on full text review, five papers were excluded for reasons according to the study protocol. A total of eight papers were included for analysis. Three papers were obtained from hand searching (7) (8) (9) (10) (11) (12) (13) (14) .
Study and patient characteristics
Overall, there were 47,706 patients with NGB, of these, 43.8% were male and the mean age was 42.8. [2011] reported much higher percentages, with 71.5% of patients in the NGB cohort, 80.9% in the SCI cohort and 86.7% in the MS cohort using this treatment. A prescription of an antimuscarinic drug (rather than any form of bladder management method), was one way in which a patient could be included into the study by , which could explain why percentage use was higher in this study, than other studies in this review. The highest use of oxybutynin of all publications was also recorded in this study (39%), followed by tolerodine (36.9%). El-Masri et al. mention that antimuscarinics were administered to those with NDO, but percentage use is not delineated.
El-Masri et al. and Chia-Cheng et al. reported the use of alpha-blockers; however, neither of the authors communicated the names of drugs. In the study by ChiaCheng et al., the most prevalent drugs amongst SCI patients with NDO were alpha-blockers, used by 33% of individuals. Alpha-blockers were administered to SCI patients with marked bladder outlet obstruction (BOO) in the study by El-Masri et al., but as with antimuscarinic use, percentage When considering studies with observations at multiple time points, El-Masri et al. reported 27% of SCI patients using assisted IC immediately before admission to the hospital; however, no patients utilized this method upon admission. During hospitalization, 4-hourly IC was the most utilized method, with 84% of patients using it at least once. This is the highest report of IC use from all publications. This markedly declined to 15.1% patients at discharge from hospital. In contrast to El-Masri et al., the use of IC increased by 10.2% in the study by Drake et al.; from 3.6% SCI patients in 1990 to 13.8% in 1996.
The difference in IC use between these two studies could be attributable to the varied follow-up. In Drake et al., changes take place over six years whereas follow up in the study by El-Masri et al. ranged between 8 and 21 years (mean 17.7).
IDC
Weld et al. reported 36.1% post-acute SCI patients that utilized IDUC and 11.4% patients had a SPC fitted. In the study by Anson et al., much lower percentages were reported, with 9.8% that used IDUC and 3.2% that used SPC. The lowest recorded use of SPC use amongst the publications was one spina bifida patient in the study by Lemelle et al. Studies with multiple observations seemed to paint a heterogeneous picture of IDC use. Overall, IDUC use substantially decreased (by 60.6%) in SCI patients, throughout the duration of the study by El-Masri et al., but the general trend was not a linear decline. SPC use decreased at a much lower rate (0.8%) from hospitalization to discharge. In contrast to this, the number of SCI patients utilizing IDUC increased by 1.6% during the study by Drake et al., and SPC use increased by 7.2%.
In the study by El-Masri et al., 69% were managed with IDUC before admission to hospital and this increased to all patients upon admission; 21% of patients utilized this method at least once during hospitalization. After discharge, 8.4% patients remained with IDUC. In the study by Drake et al., 12.2% had IDUC in 1990 and this increased to 13.8% in 1996.
The first recorded use of SPC was in the study by El-Masri et al. was during hospitalization, where 5% of patients utilized this method. After discharge, it was used by 4.2% of patients. Only 2% utilized SPC at study entry in the study by Drake et al., but this increased at a much higher rate than IDUC use, with 9.2% of patients utilizing this method at study end.
Reflex voiding (RV)
RV methods can include bladder expression (Credé), straining (Valsalva) and triggered RV (4) . In this SR, RV use was reported in four studies, varying from 2.5% to 53.1%.
RV methods are used by 25% of SCI patients in the study by Anson et 
Surgery
Two authors report use of surgery to manage bladder symptoms. Manack et al. [2009] reports particularly low numbers of bladder augmentation and interstim therapy (0.2% and 0.4% respectively) in NGB patients. This is in contrast to Lemelle et al., where the majority of spina bifida patients (55%) were surgically treated. Of these patients, 21.3% underwent bladder neck surgery, without bladder augmentation (with or without continent diversion), 36% patients underwent intestinal bladder augmentation (with or without bladder neck procedure) and 28.3% patients underwent intestinal bladder augmentation in addition to Mitrofanoff (with or without bladder neck procedure).
Other management methods
In the study by Lemelle et al., 8 .3% of people used pads and 1% of patients used an uriseath. Manack et al. [2011] reported 8.7% of patients on a combination of two or more antimuscarinic drugs; 8.3% were on two drugs, 0.4% were on three drugs and a negligible amount were on four or more drugs. A similar pattern was seen in the MS and SCI subcohorts; 9.5% patients in the MS subcohort were on a combination of two or more antimuscarinics, a further 9% were on two drugs, 0.5% were on three drugs and only two patients were on four or more drugs. When considering the SCI cohort, 9.2% patients were on a combination of two or more antimuscarinics, 8.9% were on two drugs, 0.3% were on three drugs and no patients were on four of more drugs.
Combination use Combinations of oral pharmacotherapy
A combination of alpha-blockers and antimuscarinics were given to those with detrusor sphincter dyssynergia (DSD) and autonomic dyssynergia in the study by El-Masri et al. Percentages of combination use were not reported.
Combination of a therapy with catheterization
Lemelle et al. states that 12.6% spina bifida patients regularly utilized IC in combination with oxybutynin. 90% of patients used IC in addition to surgery, including 61% through a continent neoconduit and 39% on abdominal wall.
In the study by Anson et al., 11.5% patients were on a combination of IC and reflex. There is also a report of 3.7% of patients on some combination of treatments between IC, reflex, IDUC, SPC and self-voiding, but actual combinations are not provided. Combination of surgical procedures and bladder neck injections Lemelle et al. reports 39% of patients undergoing a combination of surgical procedures to achieve reservoir and neck management in spina bifida patients. The most popular combination of procedures is intestinal bladder augmentation + Mitrofanoff principle + neck closure. Switching Weld et al. mentions that most post-acute SCI patients switched bladder management methods over the course of the study period; with the most prevalent change being from IC to IDUC (percentage is not provided); 14.3% of patients in the study by Drake et al., and one patient in the study by El-Masri et al. also made this particular switch of treatments.
As in the study by Weld et al., most patients in the study by Drake et al. switched from their original mode of management (62.8%). However, the most prevalent change in this study was straining to IC (28.9%). The most used method in 1990 was RV, and this remained the case in 1996, despite 24% switching to an alternative form of treatment.
El-Masri et al. also showed a large proportion of patients (39.5%) that switched treatments during hospitalization. In contrast to both Weld et al. and Drake et al., the most prevalent switch was IC to sphincterotomy and IDUC to IC.
Discussion
Selecting optimal treatments and employing appropriate management strategies for NGB patients is integral to improving patients' bladder symptoms and improving QoL. With passing time, clinicians have moved away from techniques associated with higher rates of complications and mortality, thus in recent years, the survival chances of NGB patients have substantially improved (15) . This SR revealed that numerous treatments have been used to manage NGB throughout the years and there has been a large variance in their use.
The most popular oral pharmacotherapy in this SR were antimuscarinics, which are cited as first line therapy for NDO in the National Institute for Health and Care Excellence (NICE), EAU and International Consultations on Incontinence (ICI) guidelines (4, 16, 17) . This conclusion should be viewed with some caution, as many studies in this review did not measure the use of oral pharmacotherapy, instead focusing their attention on other methods of bladder management. It is however well known that NDO is frequently observed in SCI (which 62.5% of included studies focused on) and antimuscarinics have acted as the primary mode of treatment for a number of years (18) .
In the study by , some patients used a combination of two or more antimuscarinics. Based on evidence from a few small clinical trials, the EAU provide a grade B recommendation, asking physicians to consider a combination of antimuscarinic agents (4, (19) (20) (21) . Other available guidelines do not provide graded recommendations on combination antimuscarinic use.
Invasive forms of management such as bladder augmentation are only employed once more conservative measures have been exhausted. A minority of spina bifida patients do not respond well to conservative treatments thus must undergo surgery to improve bladder functionality (22) . Conversely, the one study included in this SR, focusing on spina bifida, reported that the majority of patients underwent surgery. This may be due to a high severity of incontinence in this sample, higher incidence of refractory NGB or a less conservative attitude of physicians towards surgery in France between 2003-2004 (the study period).
Many of the studies in this SR have early periods of data collection therefore, it is perhaps comprehensible that some practices deviated from what is currently considered safe and effective. One example of such variance is the use of the Credé and Valsalva manoeuvres in studies that collected data in the 1980's and 1990's (7, 11) . In current guidelines, these techniques are contraindicated due to complications including epidydymoorchitis and haemorrhoids (4, 17, 23) .
IDC was also widely used (up to 100%) despite the fact that this type of catheterization is associated with an increased risk of urinary tract infection (UTI), and more serious conditions such as bladder cancer (4, 16) . It is important to remember however, that SCI can result in limited manual dexterity (e.g., in the case of tetraplegia), impeding the ability of intermittent self-catheterization (ICS) (24) . The current NICE guidelines recognise that in some instances the choice of management technique is limited by what the patient can manage (16) . Furthermore, the latest ICI guidelines suggest that assigning causation of urinary tract damage to IDC may not be accurate, as it is often utilized in patients in whom urinary tract damage has already occurred. Drake sugested that IDC may in fact be protective for the upper urinary tract (25) . Although SPC is generally prefered over IDUC, it was used at a much lower rate. This could possibly be because placement of SPC is a more invasive procedure than IDUC (17) .
This review had a global geographical scope, thus one may assume that the management methods employed reflect the healthcare system and national guidelines in which the study was conducted. At present, the American Urology Association (AUA) lacks any specific guidelines for the management of NGB. High antimuscarinic use in the two U.S. studies by Manack et al. are in line with other internationally available guidelines, where antimuscarinics are first line therapy for patients with NDO (4, 16, 17) . In the study by Chia-Cheng et al., conducted in Taiwan, alpha-blockers were the main method of management for NDO, despite Taiwanese NGB guidelines stating there is strong evidence to support the use of antimuscarinics in NDO (26) . Their use may indicate patients had retention symptoms, in conjunction to NDO. Alternatively, several small clinical trials have demonstrated efficacy of alphablockers in NDO, which could indicate that clinicians in the real world are making choices in divergence from guideline recommendations (27, 28) . This notion correlates with results from a survey conducted by Rikken et al., which showed that urologists did not follow guideline recommendations meticulously. Nevertheless, this survey also found that despite not adhering to guidelines, urologists still tended to make choices in accordance with recommendations (5) .
Three studies demonstrated notable treatment switching, which could be indicative of the dynamic progression of NGB. Duration of time since injury in SCI can have an impact on bladder compliance that can consequently influence changes in the choice of management strategy (15) . Alternatively, treatment switching may demonstrate that a trial and error approach is necessary to establish an optimal treatment regime (29) . A number of factors influence the initial choice of management method, including type of NGB, sex, age, hand dexterity and healthcare access (30) . In the study by Drake et al., reasons for switching treatments pertained to complications such as functional decline and UTI's (7). Some patients included in this review made their own treatment choices, indicating that individual preference also plays a large role (7, 11, 12 the physician and patient/their carer. In particular, NICE guidelines make specific recommendations for education of patients and their carers on the advantages and disadvantages of all available options so they are able to make informed management decisions (16, 31) .
Methodological limitations
The sensitivity of the search strategy could have been increased by including search terms for underlying neurological conditions. Additionally, publication bias and inclusion of mixed study designs could have affected the reliability of results.
Conclusions
Many treatments reported in this review are in line with current guideline recommendations; however, possibly due to the early years of data collection, some divergence was also evident. Due to the small number of studies, varied patient baseline characteristics, and selectiveness in the type of treatments and bladder management methods reported, a representative picture of real world treatment patterns in NGB could not be fully elucidated. Large epidemiological studies using electronic medical records (EMRs) are necessary to advance our understanding in how management strategies have changed over time, understand how patients are managed in current practice, and determine how well patterns relate to clinical guidelines.
